| Detailed information |
|---|
| CancerLivER ID | 2053 |
| Biomarker | CFL1 |
| Biomarker Name/Symbol (given in Publication) | CFL1 |
| Biomolecule | Protein |
| Subject | Human cell lines and Mice |
| Degree of Validity | Biomarker for prognosis and diagnosis of HBV-HCC and validated on independent dataset |
| Experimental Condition | HBV-HCC vs normal |
| Cancer type | HBV-associated Hepatocellular carcinoma |
| Regulation | Upregulated in HBV-HCC |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 27708241 |
| Type of Biomarker | Diagnostic and Prognostic |
| Pathway | lipid metabolism and CDC42-induced cytoskeleton remodeling pathways |
| Cohort | Cell lines include Huh-7, HEK293T and H22 cells; one transgenic mice (C57Bl/6) for HCC and two wild type mice C57Bl/6, p21-HBx heterozygous (p21HBx/+) mice and their C57BL/6 WT littermates were collected at the age of 12 and 24 months, when the transgenic mice (27/76, 35.53 %, and 32/70, 45.71%) res |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HBV-associated HCC |
| Year of Publication | 2016 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |